keyword
MENU ▼
Read by QxMD icon Read
search

Advanced Breast Cancer

keyword
https://www.readbyqxmd.com/read/28427084/long-term-improvement-of-breast-cancer-survivors-quality-of-life-by-a-2-week-group-physical-and-educational-intervention-5-year-update-of-the-pacthe-trial
#1
Fabrice Kwiatkowski, Marie-Ange Mouret-Reynier, Martine Duclos, François Bridon, Thierry Hanh, Isabelle Van Praagh-Doreau, Armelle Travade, Marie-Paule Vasson, Sylvie Jouvency, Christian Roques, Yves-Jean Bignon
BACKGROUND: The advantages of adapted physical activity and nutritional education (APANE) on breast cancer prognosis and quality of life (QoL) are well known, but long-term results are lacking. METHODS: A randomised controlled trial testing a 2-week intervention in hydrothermal centres including APANE enrolled 251 patients post-chemotherapy. QoL and weight control were significantly improved at 12 months. A 5-year follow-up was performed to evaluate the persistence of improvements...
April 20, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28427083/cumulative-risk-of-breast-cancer-screening-outcomes-according-to-the-presence-of-previous-benign-breast-disease-and-family-history-of-breast-cancer-supporting-personalised-screening
#2
M Román, M J Quintana, J Ferrer, M Sala, X Castells
BACKGROUND: Our aim was to assess the cumulative risk of false-positive screening results, screen-detected cancer, and interval breast cancer in mammography screening among women with and without a previous benign breast disease and a family history of breast cancer. METHODS: The cohort included 42 928 women first screened at the age of 50-51 years at three areas of the Spanish Screening Programme (Girona, and two areas in Barcelona) between 1996 and 2011, and followed up until December 2012...
April 20, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28426375/united-states-population-based-estimates-of-patient-reported-outcomes-measurement-information-system-symptom-and-functional-status-reference-values-for-individuals-with-cancer
#3
Roxanne E Jensen, Arnold L Potosky, Carol M Moinpour, Tania Lobo, David Cella, Elizabeth A Hahn, David Thissen, Ashley Wilder Smith, Jaeil Ahn, George Luta, Bryce B Reeve
Purpose To estimate cancer population-based reference values in the United States for eight PROMIS (Patient-Reported Outcomes Measurement Information System) domains by age and stage of disease. Patients and Methods For the Measuring Your Health (MY-Health) study, persons newly diagnosed with cancer (prostate, colorectal, non-small-cell lung, non-Hodgkin lymphoma, breast, uterine, or cervical) from 2010 to 2012 (N = 5,284) were recruited through the National Cancer Institute's SEER Program. Participants were mailed surveys 6 to 13 months after diagnosis...
April 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28426134/metastasis-detection-from-whole-slide-images-using-local-features-and-random-forests
#4
Mira Valkonen, Kimmo Kartasalo, Kaisa Liimatainen, Matti Nykter, Leena Latonen, Pekka Ruusuvuori
Digital pathology has led to a demand for automated detection of regions of interest, such as cancerous tissue, from scanned whole slide images. With accurate methods using image analysis and machine learning, significant speed-up, and savings in costs through increased throughput in histological assessment could be achieved. This article describes a machine learning approach for detection of cancerous tissue from scanned whole slide images. Our method is based on feature engineering and supervised learning with a random forest model...
April 20, 2017: Cytometry. Part A: the Journal of the International Society for Analytical Cytology
https://www.readbyqxmd.com/read/28425345/surrogate-marker-analysis-in-cancer-clinical-trials-through-time-to-event-mediation-techniques
#5
Sjouke Vandenberghe, Luc Duchateau, Leen Slaets, Jan Bogaerts, Stijn Vansteelandt
The meta-analytic approach is the gold standard for validation of surrogate markers, but has the drawback of requiring data from several trials. We refine modern mediation analysis techniques for time-to-event endpoints and apply them to investigate whether pathological complete response can be used as a surrogate marker for disease-free survival in the EORTC 10994/BIG 1-00 randomised phase 3 trial in which locally advanced breast cancer patients were randomised to either taxane or anthracycline based neoadjuvant chemotherapy...
January 1, 2017: Statistical Methods in Medical Research
https://www.readbyqxmd.com/read/28424227/onc201-demonstrates-anti-tumor-effects-in-both-triple-negative-and-non-triple-negative-breast-cancers-through-trail-dependent-and-trail-independent-mechanisms
#6
Marie D Ralff, Christina L B Kline, Ozan C Küçükkase, Jessica Wagner, Bora Lim, David T Dicker, Varun V Prabhu, Wolfgang Oster, Wafik S El-Deiry
Breast cancer is a major cause of cancer-related death. TRAIL has been of interest as a cancer therapeutic, but only a subset of triple negative breast cancers (TNBC) is sensitive to TRAIL. The small molecule ONC201 induces expression of TRAIL and its receptor DR5. ONC201 has entered clinical trials in advanced cancers. Here we show that ONC201 is efficacious against both TNBC and non-TNBC cells (n=13)--. A subset of TNBC and non-TNBC cells succumb to ONC201-induced cell death. In 2/8 TNBC cell lines, ONC201 treatment induces caspase-8 cleavage and cell death that is blocked by TRAIL-neutralizing antibody RIK2...
April 19, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28424130/invasive-pleomorphic-lobular-histology-is-an-adverse-prognostic-factor-on-survival-in-patients-with-breast-cancer
#7
Suleyman Sahin, Fatih Karatas, Gokmen U Erdem, Bekir Hacioglu, Kadri Altundag
Invasive pleomorphic lobular carcinoma (IPLC) is defined to be an uncommon and different subtype of classical invasive lobular carcinoma (ILC). This special variant is characterized by significant cytological atypia and pleomorphism which differs from the cytological uniformity of ILC. IPLC has been shown to have some poor prognostic factors such as axillary node metastasis and higher histological grade which may lead to poor clinical courses including a short relapse time, increased risk of recurrence and a decreased survival...
April 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/28422972/challenges-in-enumeration-of-ctcs-in-breast-cancer-using-techniques-independent-of-cytokeratin-expression
#8
John Castle, Karen Morris, Susan Pritchard, Cliona C Kirwan
INTRODUCTION: Given the current postulated plasticity between epithelial and mesenchymal states of migratory cancer cells the detection of non-epithelial CTCs is an important scientific and clinical goal. METHODS: We used the filtration-based ISET technology to enrich circulating tumour cells (CTCs) in early breast cancer blood samples and identify them using a morphology-based immunocytochemistry (ICC) approach. RESULTS: We found greater numbers of putative CTCs by this approach than by the cytokeratin-based CellSearch technology, but a high number of CTC false positives were identified in healthy volunteer samples which were not reduced in successive blood draws...
2017: PloS One
https://www.readbyqxmd.com/read/28420722/low-tumor-mitochondrial-dna-content-is-associated-with-better-outcome-in-breast-cancer-patients-receiving-anthracycline-based-chemotherapy
#9
Marjolein J A Weerts, Antoinette Hollestelle, Anieta M Sieuwerts, John A Foekens, Stefan Sleijfer, John W M Martens
In this study, we aimed to explore whether low levels of mitochondrial DNA (mtDNA) content in the primary tumor could predict better outcome for breast cancer patients receiving anthracycline-based therapies. We hypothesized that tumor cells with low mtDNA content are more susceptible to mitochondrial damage induced by anthracyclines, and thus are more susceptible to anthracycline treatment.<br /><br />Experimental Design: We measured mtDNA content by a quantitative PCR approach in 295 primary breast tumor specimens originating from two well-defined cohorts: 174 lymph node-positive patients who received adjuvant chemotherapy and 121 patients with advanced disease who received chemotherapy as first-line palliative treatment...
April 18, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28420149/advanced-stage-at-presentation-remains-a-major-factor-contributing-to-breast-cancer-survival-disparity-between-public-and-private-hospitals-in-a-middle-income-country
#10
Yek-Ching Kong, Nirmala Bhoo-Pathy, Shridevi Subramaniam, Nanthini Bhoo-Pathy, Nur Aishah Taib, Suniza Jamaris, Kiran Kaur, Mee-Hoong See, Gwo-Fuang Ho, Cheng-Har Yip
Background: Survival disparities in cancer are known to occur between public and private hospitals. We compared breast cancer presentation, treatment and survival between a public academic hospital and a private hospital in a middle-income country. Methods: The demographics, clinical characteristics, treatment and overall survival (OS) of 2767 patients with invasive breast carcinoma diagnosed between 2001 and 2011 in the public hospital were compared with 1199 patients from the private hospital. Results: Compared to patients in the private hospital, patients from the public hospital were older at presentation, and had more advanced cancer stages...
April 16, 2017: International Journal of Environmental Research and Public Health
https://www.readbyqxmd.com/read/28419909/reduction-in-advanced-breast-cancer-after-introduction-of-a-mammography-screening-program-in-tyrol-austria
#11
W Oberaigner, Sabine Geiger-Gritsch, M Edlinger, M Daniaux, R Knapp, M Hubalek, U Siebert, C Marth, W Buchberger
BACKGROUND: We analysed all female breast cancer (BC) cases in Tyrol/Austria regarding the shift in cancer characteristics, especially the shift in advanced BC, for the group exposed to screening as compared to the group unexposed to screening. METHODS: The analysis was based on all BC cases diagnosed in women aged 40-69 years, resident in Tyrol, and diagnosed between 2009 and 2013. The data were linked to the Tyrolean mammography screening programme database to classify BC cases as "exposed to screening" or "unexposed to screening"...
April 15, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28419480/characterization-of-neutropenia-in-advanced-cancer-patients-following-palbociclib-treatment-using-a-population-pharmacokinetic-pharmacodynamic-modeling-and-simulation-approach
#12
Wan Sun, Peter J O'Dwyer, Richard S Finn, Ana Ruiz-Garcia, Geoffrey I Shapiro, Gary K Schwartz, Angela DeMichele, Diane Wang
Neutropenia is the most commonly reported hematologic toxicity following treatment with palbociclib, a cyclin-dependent kinase 4/6 inhibitor approved for metastatic breast cancer. Using data from 185 advanced cancer patients receiving palbociclib in 3 clinical trials, a pharmacokinetic-pharmacodynamic model was developed to describe the time course of absolute neutrophil count (ANC) and quantify the exposure-response relationship for neutropenia. These analyses help in understanding neutropenia associated with palbociclib and its comparison with chemotherapy-induced neutropenia...
April 18, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28419141/ghrelin-is-a-prognostic-marker-and-a-potential-therapeutic-target-in-breast-cancer
#13
Malin Grönberg, Cecilia Ahlin, Ylva Naeser, Eva Tiensuu Janson, Lars Holmberg, Marie-Louise Fjällskog
Ghrelin and obestatin are gastrointestinal peptides, encoded by the same preproghrelin gene. Both are expressed in breast cancer tissue and ghrelin has been implicated in breast cancer tumorigenesis. Despite recent advances in breast cancer management the need for new prognostic markers and potential therapeutic targets in breast cancer remains high. We studied the prognostic impact of ghrelin and obestatin in women with node negative breast cancer. Within a cohort of women with breast cancer with tumor size ≤ 50 mm, no lymph node metastases and no initiation of adjuvant chemotherapy, 190 women were identified who died from breast cancer and randomly selected 190 women alive at the corresponding time as controls...
2017: PloS One
https://www.readbyqxmd.com/read/28419079/predicting-breast-cancer-response-to-neoadjuvant-chemotherapy-using-pretreatment-diffuse-optical-spectroscopic-texture-analysis
#14
William T Tran, Mehrdad J Gangeh, Lakshmanan Sannachi, Lee Chin, Elyse Watkins, Silvio G Bruni, Rashin Fallah Rastegar, Belinda Curpen, Maureen Trudeau, Sonal Gandhi, Martin Yaffe, Elzbieta Slodkowska, Charmaine Childs, Ali Sadeghi-Naini, Gregory J Czarnota
BACKGROUND: Diffuse optical spectroscopy (DOS) has been demonstrated capable of monitoring response to neoadjuvant chemotherapy (NAC) in locally advanced breast cancer (LABC) patients. In this study, we evaluate texture features of pretreatment DOS functional maps for predicting LABC response to NAC. METHODS: Locally advanced breast cancer patients (n=37) underwent DOS breast imaging before starting NAC. Breast tissue parametric maps were constructed and texture analyses were performed based on grey-level co-occurrence matrices for feature extraction...
April 18, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28419078/targeting-of-ccbe1-by-mir-330-3p-in-human-breast-cancer-promotes-metastasis
#15
Aruz Mesci, Xiaoyong Huang, Samira Taeb, Sahar Jahangiri, Yohan Kim, Emmanouil Fokas, Jeff Bruce, Hon S Leong, Stanley K Liu
BACKGROUND: MicroRNAs (miRs) are involved in the regulation of many processes that contribute to malignancy, including cell proliferation, radiation resistance, invasion and metastasis. The role of miR-330-3p, an miR upregulated in breast cancer, remains unclear. METHODS: We examine the association of miR-330-3p with distant relapse-free survival in the Oxford cohort of breast cancer patients. We also study miR-330-3p function using in vitro invasion and ex ovo metastasis assays...
April 18, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28417244/ribociclib-first-global-approval
#16
Yahiya Y Syed
Ribociclib is an oral, small-molecule inhibitor of cyclin-dependent kinase (CDK) 4 and 6 that is under development by Novartis for the treatment of cancer. CDKs play an important role in cell cycle progression and cellular proliferation, and inhibition of these kinases with ribociclib results in G1 phase cell-cycle arrest. Ribociclib, in combination with an aromatase inhibitor, was recently approved in the USA for the first-line treatment of advanced breast cancer and has been submitted for approval in the EU for this indication...
April 17, 2017: Drugs
https://www.readbyqxmd.com/read/28415882/rage-receptor-targeted-bioconjuguate-lipid-nanoparticles-of-diallyl-disulfide-for-improved-apoptotic-activity-in-triple-negative-breast-cancer-in-vitro-studies
#17
Venkata Talluri Siddhartha, Sai Kiran S S Pindiprolu, Pavan Kumar Chintamaneni, Shashank Tummala, S Nandha Kumar
In the present study, we have demonstrated receptor for advanced glycation endproducts (RAGE) as a target for delivery of drugs specifically to triple negative breast cancer cells. We have prepared solid lipid nanoparticle formulation of cytotoxic agent di-allyl-disulfide (DADS) to overcome its bioavailability issues. Then, we have surface modified DADS-loaded solid lipid nanoparticles (DADS-SLN) with RAGE antibody to achieve site-specific delivery of DADS to TNBC cells. We found a significant cellular internalization of RAGE surface modified DADS-SLN (DADS-RAGE-SLN) when compared to DADS-SLN...
April 17, 2017: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/28415808/ikk-inhibition-by-bms-345541-suppresses-breast-tumorigenesis-and-metastases-by-targeting-gd2-cancer-stem-cells
#18
Venkata Lokesh Battula, Khoa Nguyen, Jeff Sun, Mary Kathryn Pitner, Bin Yuan, Chandra Bartholomeusz, Numsen Hail, Michael Andreeff
We have identified that the ganglioside GD2 is a marker for breast cancer stem cells (BCSCs), and that targeting the enzyme GD3 synthase (GD3S, which regulates GD2 biosynthesis) reduces breast tumorigenesis. The pathways regulating GD2 expression, and their anomalous functions in BCSC, are unclear. Proteomic analysis of GD2+ and GD2- cells from breast cancer cell lines revealed the activation of NFκB signaling in GD2+ cells. Dose- and time-dependent suppression of NFκB signaling by the small molecule inhibitor BMS-345541 reduced GD2+ cells by > 90%...
March 16, 2017: Oncotarget
https://www.readbyqxmd.com/read/28415615/a-nation-wide-multicenter-10-year-1999-2008-retrospective-study-of-chemotherapy-in-chinese-breast-cancer-patients
#19
Qiao Li, Zhao Yang, Jinhu Fan, Jianjun He, Bin Zhang, Hongjian Yang, Xiaoming Xie, Zhonghua Tang, Hui Li, Youlin Qiao, Pin Zhang
Little information is available on the evolvement of chemotherapeutic regimens administered to Chinese females with breast cancer. We retrospectively analyzed demographic, pathological and chemotherapeutic data of 4211 breast cancer patients, who were randomly selected from representative hospitals of 7 traditional areas in China between 1999 and 2008. A total of 3271 cases (77.7%) received adjuvant chemotherapy, 558 (13.3%) received neoadjuvant chemotherapy, and 392 (9.3%) received chemotherapy for metastatic disease...
March 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28415567/efficacy-and-safety-of-t-dm1-in-the-common-practice-of-her2-advanced-breast-cancer-setting-a-multicenter-study
#20
Alessandra Fabi, Michelino De Laurentiis, Michele Caruso, Enrichetta Valle, Luca Moscetti, Daniele Santini, Katia Cannita, Luisa Carbognin, Mariangela Ciccarese, Rosalba Rossello, Grazia Arpino, Vita Leonardi, Filippo Montemurro, Nicla La Verde, Daniele Generali, Alberto Zambelli, Giuseppa Scandurra, Michelangelo Russillo, Ida Paris, Anna Maria D'Ottavio, Gianfranco Filippelli, Marianna Giampaglia, Simonetta Stani, Agnese Fabbri, Daniele Alesini, Daniela Cianniello, Diana Giannarelli, Francesco Cognetti
Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancer (mBC). The aim of this 'field-practice' study was to investigate the efficacy and safety of T-DM1, focusing on treatment line, previous lapatinib treatment and patterns of metastasis. Three hundred and three patients with HER2-positive mBC who received T-DM1 were identified by reviewing the medical records of 24 Italian Institutions...
March 18, 2017: Oncotarget
keyword
keyword
24054
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"